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mune response of a self-amplifying mRNA (sa-RNA) after elec-
troporation and lipid-nanoparticle (LNP)-mediated delivery in
the skin of mice. Intradermal electroporation of the sa-RNA
resulted in a plateau-shaped expression, with the plateau
between day 3 and day 10. The overall protein expression of
sa-RNA was signiﬁcantly higher than that obtained after elec-
troporation of plasmid DNA (pDNA) or non-replication
mRNAs. Moreover, using IFN-b reporter mice, we elucidated
that intradermal electroporation of sa-RNA induced a short-
lived moderate innate immune response, which did not affect
the expression of the sa-RNA. A completely different expres-
sion proﬁle and innate immune response were observed when
LNPs were used. The expression peaked 24 h after intradermal
injection of sa-RNA-LNPs and subsequently showed a sharp
drop. This drop might be explained by a translational blockage
caused by the strong innate immune response that we observed
in IFN-b reporter mice shortly (4 h) after intradermal injection
of sa-RNA-LNPs. A ﬁnal interesting observation was the capac-
ity of sa-RNA-LNPs to transfect the draining lymph nodes after
intradermal injection.Received 1 April 2019; accepted 1 August 2019;
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Synthetic mRNAs are currently intensively studied for protein
(replacement) therapy, gene editing, stem cell reprogramming,
and immunotherapy.1–3 Each application requires distinct mRNA
properties. For instance, protein (replacement) therapy asks for a
long-acting and innate immunosilent mRNA, while mRNA vacci-
nation may require opposite characteristics. Multiple synthetic
mRNA platforms, such as unmodiﬁed mRNA, nucleoside-modiﬁed
mRNA, and self-amplifying mRNA (sa-RNA) are currently avail-
able. To ﬁnd the right match between the foreseen therapeutic
application and the mRNA platform, information on the in vivo
expression kinetics and innate immune response of these different
mRNA platforms is crucial. Nucleoside-modiﬁed mRNAs are
considered innate immunosilent,4 and sa-RNAs are long actingMolecular Therapy
This is an open access article under the CC BY-NC-as they contain the coding sequences of a viral replicase complex
that ensures ampliﬁcation of the complete sa-RNA strand and,
especially, the shorter subgenomic mRNA strand that contains
the gene of interest.5–7 The ampliﬁcation and abundance of these
subgenomic mRNAs engender a high protein production. The viral
replicase complex in sa-RNA originates from a single-stranded
positive-sense RNA virus like, e.g., Venezuelan equine encephalitis
virus (VEEV).7–10
In vitro-transcribed mRNA (IVT mRNA) can be delivered in vivo
using non-viral carriers such as lipid nanoparticles (LNPs)11–13 and
physical methods such as electroporation.14–16 Non-viral carriers
formulate the mRNA into nanoparticles that enter the cells by
endocytosis, while it is believed that physical methods like electro-
poration mainly deliver the mRNA directly in the cytosol via tem-
poral cell-membrane perforations.12,17 One can expect that these
different delivery mechanisms will inﬂuence the expression efﬁcacy
as well as the extent to which the innate immune system recognizes
this synthetic mRNA.18 The innate immune system recognizes IVT
mRNA by pathogen recognition receptors (PRRs) that are located
in the endosomes (Toll-like receptors [TLRs] 3, 7, and 8) and in
the cytoplasm (e.g., retinoic-acid-inducible gene I [RIG-I]-like re-
ceptors). Activation of these PRRs results in the induction of nu-
clear factor kB (NF-kB), caspase 1, and interferon regulatory fac-
tors 3 and 7 (IRF3 and IRF7, respectively), which respectively
leads to the production of pro-inﬂammatory cytokines, cell death,
and type I interferons (IFNs).19 Type I IFNs are known to activate
20,50-oligoadenylate synthetase (OAS) and protein kinase R
(PKR).10 The former subsequently activates an endonuclease
(RNaseL) that degrades the intracellular mRNA, while the latter: Nucleic Acids Vol. 17 September 2019 ª 2019 The Author(s). 867
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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actions will decrease the translation of the introduced synthetic
mRNA. Furthermore, extensive activation of caspase-1 by synthetic
mRNA can also cause pyroptosis, a form of immunogenic cell
death that exhibits features of apoptosis as well as necrosis.19,22
For certain applications like protein (replacement) therapy, a
repeated administration of the mRNA will be required. For these
applications, it will be important to control not only the extent
of the innate immune response but also the duration of the innate
immune response. Indeed, if the innate immune response has not
faded away at the moment of the next mRNA injection, a chronical
inﬂammatory condition will be established. The duration of
the innate immune response after in vivo delivery of mRNA is
not well studied, and most information comes from studies that
used RT-PCR or ELISA to quantify key innate immune
proteins.23–25 Although RT-PCR is a very sensitive technique, the
correlations between mRNA levels and protein expression
are not always linear.26 On the other hand, ELISA may not be
sensitive enough to detect moderate innate immune responses in
the excised tissues.27,28 Furthermore, analyzing the in vivo innate
immune response in tissues by RT-PCR and ELISA is invasive
and, therefore, cannot be used to follow up the innate immune
response in one and the same mouse. Therefore, reporter mice
like, e.g., the IFN-b luciferase reporter mice may serve as a sensi-
tive and reliable alternative to monitor the extent, duration, and
location of the innate immune responses after mRNA delivery in
mice.28
Recently, we developed, in collaboration with the laboratory of
Ron Weiss (Department of Biological Engineering, Massachusetts
Institute of Technology, Cambridge, MA, USA), a new sa-RNA.
This sa-RNA has the capacity to overcome innate immune
responses as it encodes the non-structural proteins (nsPs) of
VEEV, which are known to impair critical signaling events down-
stream of the type I IFN receptor, leading to disruption of STAT1
signaling.29 In this study, we determined the in vivo efﬁcacy and
innate immunity of this novel VEEV-based sa-RNA at different
doses and benchmarked it against plasmid DNA (pDNA) as well
as unmodiﬁed and N1-methylpseudouridine (m1c)-modiﬁed
synthetic mRNA. To avoid carrier-related effects on the efﬁciency
and innate immunogenicity of these vectors, in vivo electro-
poration was used to compare the in vivo performance of these
vectors. Electroporation- and carrier-mediated deliveries of
mRNA occur by completely different mechanisms. As it is
currently not known to which extend these different delivery
mechanisms affect the in vivo performance of synthetic mRNA,
we formulated our sa-RNA into LNPs and compared the expres-
sion proﬁle and innate immune response with that obtained after
in vivo electroporation. Because of our interest in mRNA vaccina-
tion, intradermal delivery was used, as the skin is extremely
immune competent and easily accessible.30 Our interest in
mRNA vaccination also inspired us to study the mRNA expression
in the draining lymph nodes as an indicator of mRNA transfection
in antigen-presenting cells.868 Molecular Therapy: Nucleic Acids Vol. 17 September 2019RESULTS
Electroporation Increases the Expression of sa-RNA and pDNA
after Intradermal Injection
In the ﬁrst set of experiments, the expression kinetics after intrader-
mal injection of pDNA or sa-RNA with or without subsequent
electroporation was studied in BALB/c mice. The intradermal deliv-
ery route was selected, as the skin is a large, accessible organ contain-
ing many antigen-presenting cells (APCs) for initiating an effective
immune response. With both vectors, the luciferase expression could
be detected as early as 5 h after injection. Electroporation increased
the expression of pDNA as well as sa-RNA. However, the beneﬁcial
effect of electroporation on pDNA transfection was only observed
during the ﬁrst 5 days (Figure 1A). The peak in luciferase expression
after intradermal electroporation of pDNA was reached after 2 days,
and at this time point, electroporation induced a 3.5-fold increase in
expression. The beneﬁcial effect of electroporation was much more
pronounced for sa-RNA (Figure 1B). The luciferase expression proﬁle
of the sa-RNAwas also different from that of pDNA. sa-RNA reached
its maximal expression 8–10 days after injection, and at this moment,
electroporation caused a 40-fold increase in expression compared to
naked delivery. After 28 days, the expression of the sa-RNA had
declined to background, while the expression of pDNA lasted longer
than 28 days. To allow for a better comparison of the expression
levels, the areas under the curve (AUCs) were calculated (Figure 1C).
After intradermal electroporation of sa-RNA, the total amount of
luciferase produced during the follow-up period was signiﬁcantly
higher (30-fold higher) than after intradermal electroporation of
pDNA (Figure 1C). Furthermore, the overall expression of intrader-
mally administered pDNA and sa-RNA was increased 3-fold and
21-fold, respectively, by electroporation. These data demonstrate
again that, especially, the expression of sa-RNA and, to a lesser extent,
pDNA is increased by electroporation and that the sa-RNA clearly
outperforms pDNA after intradermal electroporation.Comparison of the Dose-Dependent Expression of sa-RNA,
Non-replicating mRNAs, and pDNA
Besides sa-RNA and pDNA, non-replicating mRNAs, regardless of
whether they contain modiﬁed nucleosides, are currently also inten-
sively studied for vaccination, gene editing, or protein replacement
therapy applications. However, a side-by-side comparison of the
dose-expression proﬁles of these different synthetic mRNA platforms
and pDNA after in vivo electroporation has not been performed.
Therefore, we studied the luciferase expression levels and kinetics
after intradermal electroporation of 10, 5, or 1 mg sa-RNA, m1c-
modiﬁed mRNA, and unmodiﬁed mRNA or pDNA (Figures 2A–
2C). The non-replicating mRNAs and pDNA reached, independent
of the dose, their peak expression 5 h and 3 days, respectively, after
transfection. After this point, the expression of the non-replicating
mRNAs steadily decreased and disappeared at day 14 or day 10,
when only 1 mg was used. pDNA showed, after its peak, a less steep
drop, and the expression of the two highest doses clearly remained
above background until the end of the follow-up period. The expres-
sion proﬁle of sa-RNA was different and reached, unrelated to the
Figure 1. Effect of Intradermal Electroporation on the Expression Kinetics
of sa-RNA and pDNA
(A and B) The in vivo bioluminescence was measured at different time points after
intradermal injection of 5 mg of either pDNA (A) or sa-RNA (B), without ( EP) or with
(+ EP) electroporation using needle array electrodes. Per group, three mice were
injected on each flank (n = 6). Results are indicated asmean ± SEM of the total flux in
the regions of interest (ROIs). The dotted black line represents the background
signal. The shaded area indicates significant differences between the expression
with and without electroporation. (C) AUC of the curves represented in (A) and (B)
(mean ± SEM). **p < 0.01.
www.moleculartherapy.orgdose, a maximal plateau expression between day 3 and day 10. After
this plateau, the expression showed a gradual drop, and background
levels were reached during the follow-up period (i.e., at days 28 and
21) with the two lowest doses (i.e., 5 and 1 mg, respectively). The
largest difference was reached 10 days after injection, as sa-RNA
was still inducing maximum luciferase expression, while the non-
replicating mRNAs had almost reached background level.
To gain more insight into the dose dependence, the total protein
expression was evaluated by calculating the AUC of the dose-
response curves over a period of 4 weeks after injection (Figure 2D).
These AUCs nicely show a signiﬁcant higher protein expression
after sa-RNA transfection compared to pDNA and non-replicating
mRNA. The m1c modiﬁcation induced more protein expression
compared to the non-modiﬁed variant (when 10 or 5 mg was
used) but less than pDNA or sa-RNA. A striking observation
is that 10 or 5 mg of the non-replicating mRNAs result in a
similar expression curve and produce comparable amounts of
luciferase during the follow-up period (Figures 2A, 2B, and 2D).
sa-RNA at Nanogram Doses Follows an All-or-Nothing Pattern
The high expression of 1 mg sa-RNA (Figure 2C) and the fact that
sa-RNA can amplify itself after intracellular delivery encouraged us
to examine the expression when doses as low as 10 ng were intra-
dermally electroporated (Figure 3). At these submicron doses, the
sa-RNA showed an all-or-nothing pattern: injection either resulted
in a very high expression of luciferase or no expression at all. An
overview of the success rates as a function of the sa-RNA dose is
given in Table 1. An intradermal electroporation of sa-RNA was
considered successful when the luciferase expression generated a
total ﬂux above 106 photons per second (i.e., 200-fold above the
background signal) during at least 4 consecutive days. A high
dose of 10 mg was successful in 6 out of 6 attempts, while the
lowest dose of 10 ng only initiated expression in 1 out of 6
attempts. All successful injections resulted, independent of
the dose (except at the lowest dose, i.e., 10 ng), in similar ex-
pression levels and curves with a maximal plateau expression
between circa days 3 and 10. Submicron doses of pDNA were
also assessed and resulted in much lower expression levels than
those of sa-RNA, and they showed a clear dose-dependent proﬁle.
Ten nanograms of pDNA gave almost no luciferase expression,
whereas 10 mg pDNA (Figure 2A) reached peak luciferase levels
comparable to those obtained with the successful injection of
10 ng sa-RNA.
Kinetics of the Type I IFN Response after Intradermal
Electroporation of sa-RNA, Non-replicating mRNAs, and pDNA
To acquire information about the extent of the induced innate im-
mune response, we evaluated the level and duration of IFN-b induc-
tion upon intradermal electroporation of the different synthetic
mRNAs, pDNA, and buffer in IFN-b reporter mice (Figure 4). Elec-
troporation of buffer did not provoke a notable increase in IFN-b,
while all the vectors caused a clear IFN-b response that reached its
maximum 8 h after injection.Molecular Therapy: Nucleic Acids Vol. 17 September 2019 869
Figure 2. Dose-Dependent Expression Kinetics after
Intradermal Electroporation of pDNA, sa-RNA, and
Unmodified and m1c-Modified mRNA in Mice
(A–C) Three mice were intradermally electroporated in both
flanks with 10 mg (A), 5 mg (B), or 1 mg (C) of each vector
(n = 6). In vivo bioluminescence was measured over
4 weeks, and mean ± SEM of the total flux in the ROIs is
displayed. The dotted line represents the background
signal. The shaded area indicates a significant difference
between the luciferase expression of sa-RNA compared to
pDNA, modified mRNA, and unmodified mRNA, except for
10 mg after 3 days (no significance) and 10 mg and 1 mg
after 5 days (only significant difference between sa-RNA
and the non-replicating mRNAs). (D) AUC (mean ± SEM) of
the expression kinetic curves shown in (A)–(C). *p < 0.05;
**p < 0.01; ***p < 0.001; ****p < 0.0001.
Molecular Therapy: Nucleic AcidsThe highest IFN-b response was observed with the non-replicating
mRNAs. Modiﬁed mRNA induced the highest average IFN-b in-
duction shortly after electroporation, followed by unmodiﬁed
mRNA. However, after 3 days, the IFN-b response induced by
the mRNAs becomes similar. IFN-b induction returns to baseline
level 7 days after electroporation of mRNA. This led to an overall
non-signiﬁcant higher innate immune response induced by modi-
ﬁed mRNA (Figure 4B). Self-amplifying mRNA caused, especially
shortly after administration, a slightly lower IFN-b response
than the non-replicating mRNAs. However, the IFN-b response
dropped slower after administration of the sa-RNA, resulting in
an IFN-b response similar to that of unmodiﬁed mRNA from
day 3 onward. No signiﬁcant induction of IFN-b was noticed after
the administration of pDNA. The induction reached its maximum
1 day after administration and subsequently declined to back-
ground around day 4.
Electroporation versus Lipid-Nanoparticle-Mediated Delivery of
sa-RNA
In the next experiment, we compared the expression of 5 mg sa-
RNA formulated into state-of-the-art LNPs with that of naked
sa-RNA with or without subsequent electroporation. sa-RNAs
formulated into LNPs showed completely different expression pro-
ﬁles compared to those of naked or electroporated sa-RNA after
intradermal administration (Figure 5A). LNP-mediated transfec-
tion of sa-RNA resulted in an early-peak luciferase expression
24 h after injection. After this time point, the expression showed
a very steep drop. However, after 7 days, a slight resurgence in
luciferase expression occurred. As reported in Figure 1, the
expression of the naked sa-RNA was, again, clearly increased by
electroporation. The shapes of the expression proﬁles of non-elec-870 Molecular Therapy: Nucleic Acids Vol. 17 September 2019troporated and electroporated sa-RNA were
similar: a sharp increase during the ﬁrst 24 h
and, subsequently, a steady increase until the
maximal expression levels were reached around
8–10 days after injection. After day 10, the
luciferase expression gradually dropped, and28 days after administration, the expression of the naked,
electroporated, and LNP-delivered sa-RNA became close to
background.
For certain applications such as protein (replacement) therapy,
the total amount of produced protein over time is more relevant
than the peak expression level. Therefore, we calculated
the AUCs shown in Figures 5A and 5C. The protein production
after electroporation of the sa-RNA was, respectively, 22-fold
and 4-fold higher than the amount of protein produced after
injection of, respectively, naked or LNP-formulated sa-RNA
(Figure 5B).
We also studied the dose-dependent expression after intradermal in-
jection of sa-RNA-LNPs. Doses lower than 5 mg, i.e., 1 and 0.1 mg, of
the LNP-formulated sa-RNA resulted in similar but lower expres-
sion proﬁles (Figures 5C and 5D). With the lower doses (i.e., 0.1
and 1 mg), a similar resurgence of the luciferase is noticed as with
the 5-mg dose. However, this resurgence was more pronounced,
and the lower the dose, the earlier this resurgence was noticed. All
injections of sa-RNA-LNPs resulted in a successful expression.
sa-RNA Formulated in LNPs Cause Expression in the Draining
Lymph Node after Intradermal Injection
During evaluation of the LNP-formulated sa-RNA, we observed a sec-
ond, clearly delineated, smaller bioluminescent spot next to the injec-
tion spot (Figure 6). This spot was located at the position where the
subiliac lymph node can be found and, hence, suggested expression
of the sa-RNA in the draining lymph node.31 This additional expres-
sion spot could be seen until 48 h after administration (data not
shown).
Figure 3. Expression Kinetics of Low Doses of sa-RNA and pDNA after Intradermal Electroporation
(A and B) Doses from 0.5 to 0.01 mg of sa-RNA (A) or pDNA (B) were intradermally electroporated, and luciferase expression was monitored during 4 weeks by in vivo
bioluminescence imaging. Only sa-RNA administrations that resulted in a successful expression are used to calculate the mean. Results are indicated as mean ± SEM of the
total flux in the ROIs. Six administrations were performed. However, for the sa-RNA, not all intradermal electroporations resulted in a successful expression. The
administrations that were successful are shown in (A) (n values were 4, 2, 4, and 1 for 0.5, 0.1, 0.05, and 0.01 mg sa-RNA, respectively).
www.moleculartherapy.orgTo conﬁrm this observation, mice were euthanized 24 h after
intradermal injection of sa-RNA-LNPs, and the ipsilateral and
contralateral (negative) subiliac lymph nodes were excised to be
imaged ex vivo (Figures 6 and 7). The ipsilateral (positive) subiliac
lymph nodes showed signiﬁcantly higher luciferase expression
compared to the contralateral (negative) lymph nodes. This indicates
either that transfected APCs traveled from the injection spot to the
draining ipsilateral subiliac lymph node or that the sa-RNA-LNPs
traveled to the ipsilateral subiliac lymph node and transfected APCs
and/or lymph node stromal cells at this site. Such transfection in
the draining lymph nodes was not observed after injection of the
same dose of naked sa-RNA with or without electroporation.
Kinetics of the Type I IFN Immune Response after Lipid-
Nanoparticle- and Electroporation-Mediated Delivery of sa-RNA
Self-amplifying mRNA formulated in LNPs will enter the cells
through endosomes, which will likely lead to stimulation of the
endosomal TLRs. It is expected that these TLRs get shunned when
electroporation is used. To study whether this difference in cellular
uptake affects the IFN-b response, we compared the kinetics of the
IFN-b response after LNP- and electroporation-mediated delivery
of the sa-RNA (Figure 8). Intradermal injection of 5 mg sa-RNA-
LNPs caused, compared to intradermal electroporation, a higher
IFN-b response that also lasted longer: after LNP-mediated delivery
of sa-RNA, IFN-b induction persisted for 14 days, whereas elec-
troporation-mediated delivery only induced an IFN-b response
during 7 days after injection. During the 14-day follow-up period,
the IFN-b response was about 8-fold higher after LNP-mediated
delivery.
DISCUSSION
The use of synthetic mRNA for the in vivo production of therapeu-
tic proteins like, e.g., antibodies, erythropoietin, or blood-clottingfactors, is recently gaining more and more attention.32–34 For these ap-
plications, a long-acting mRNA that can produce therapeutic proteins
during several weeks would be ideal. Additionally, activation of the
innate immune system by the delivered synthetic mRNA should be
as low as possible, or at least it should not affect the translation of the
synthetic mRNA. Our data demonstrate that in vivo electroporation
of a VEEV-based sa-RNA meets the aforementioned criteria. Electro-
poration of this sa-RNA caused a high and stable expression over
2weeks. In contrast, non-replicating unmodiﬁed andmodiﬁedmRNAs
resulted in a much lower and shorter protein production. sa-RNAs
based on, e.g., VEEV have been evaluated in the past as a possible
new vaccination platform.6,35–38 However, the in vivo expression ki-
netics and, especially, the inherent innate immunity of VEEV-based
sa-RNAs have not been studied in detail. We found that the sa-RNA
caused, despite its intracellular ampliﬁcation, a lower innate immune
response than the non-replicating unmodiﬁed and modiﬁed mRNAs.
Nevertheless, the kinetics of the IFN-b response was similar between
sa-RNAandnon-replicatingmRNAs, with amaximal IFN-b induction
5 h after administration followed by a steady decline. This may indicate
that mainly the introduced sa-RNA, and not the replication of the sa-
RNA, is causing the innate immune response. The absence of a strong
and prolonged innate immune response after in vivo delivery of our
VEEV-based sa-RNA can be explained by the capacity of the nsPs of
VEEV to impair the signaling downstream of the type I IFN receptor.29
Additionally, it has been reported that nsP2 can shut off the translation
of host mRNA by blocking its nuclear export.39–41 These actions of the
nsPs of VEEVmay temper the innate immune response and prevent it
from going into full swing during the replication of our VEEV-based
sa-RNA.
sa-RNAs generate a replicase complex that is composed of the nsP1–4
of a single-stranded RNA virus. This raises the concern that these
viral proteins may elicit an adaptive immune response, which wouldMolecular Therapy: Nucleic Acids Vol. 17 September 2019 871
Table 1. Rate of Successful sa-RNA Injections
Dose (mg) Successful Injections Total Injections Rate (%)
10 6 6 100
5 6 7 85.7
1 5 8 62.5
0.5 4 6 66.7
0.1 2 6 33.3
0.05 4 6 66.7
0.01 1 6 16.7
Molecular Therapy: Nucleic Acidsimpede repeated administration of sa-RNAs. However, we have
strong indications that such neutralizing adaptive immune response
is not established. Indeed, we observed that re-administration of
our VEEV-based sa-RNA after 4 weeks did not result in a lower pro-
tein expression (unpublished data).
We showed that sa-RNAs are very potent vectors, as they can cause
gene expression at doses as low as 10 ng after local administration
in mice. However, it is important to mention that electroporation
of 10 ng sa-RNA was only successful in 1 out of 6 injections. By eval-
uating the success rate as a function of the dose, we found that the per-
centage of successful injections gradually dropped when the dose of
sa-RNA was lowered. We recently showed that this observation
may be attributed to the presence of RNases and that the repeatability
and efﬁcacy of intradermal electroporated sa-RNA can be increased
by adding a protein-based RNase inhibitor to the sa-RNA just before
injection.42 RNases are abundantly present on the skin,43 and these
RNases can contaminate the tip of the needle during injection. In
this way, minuscule amounts of RNases may be introduced and espe-
cially low doses of sa-RNAs will be very sensitive to such contami-
nating RNases.
To overcome activation of the RNA sensors, the mRNA can be
rendered less immunogenic through incorporation of modiﬁed nucle-
otides like pseudouridine, 5-methylcytidine, and N1-methylpseu-
douridine.44–47 However, incorporation of N1-methylpseudouri-
dine-modiﬁed nucleosides in our non-replicating mRNA did not
reduce the innate immune response; hence, no signiﬁcant increases
in protein production were observed after electroporation of
nucleoside-modiﬁed mRNAs. Similar results have been reported by
Kauffman et al.,48 who found that incorporation of pseudouridine-
modiﬁed nucleosides had no signiﬁcant effect on either immunoge-
nicity or protein expression of mRNA-LNPs after systemic injection.
In our work and in that of Kauffman et al., the mRNA was not puri-
ﬁed by high-pressure liquid chromatography (HPLC); hence, double-
stranded mRNA or short aborted mRNA species that are known to be
highly immunogenic were probably not completely removed, causing
the innate immune response.
Although the expression of pDNA is lower than that of sa-RNA dur-
ing the ﬁrst weeks, pDNA is still an interesting vector for protein872 Molecular Therapy: Nucleic Acids Vol. 17 September 2019(replacement) therapy, as its expression lasts longer than that of sa-
RNA (up to 5 months after intradermal injection).49 CpG motifs in
the pDNA as well as LPS contamination during pDNA preparation
can result in, respectively, TLR9 and TLR4 activation, leading to
IFN-b induction. However, in our hands, the innate immune
response after intradermal pDNA electroporation was very low and
short-lived compared to mRNA vectors (Figure 4A), which further
supports the use of pDNA for protein therapy. Since we use an endo-
toxin-removing puriﬁcation kit for the preparation of the pDNA,
most of the IFN-b response observed in Figure 4A is probably due
to the CpG motifs in the pDNA. Nevertheless, the use of pDNA
has some drawbacks like, e.g., the theoretical risk of genomic integra-
tion and oncogenic mutagenesis; the presence of antibiotic-resistance
genes; and the fact that, for certain therapeutic proteins, an uncon-
trolled expression during several months is not warranted.
To study the effect of different delivery methods on the in vivo perfor-
mance of our VEEV-based sa-RNA, we encapsulated the sa-RNA into
LNPs. Intradermal injection of these sa-RNA-LNPs resulted in a
completely different expression proﬁle than obtained after intra-
dermal electroporation. Indeed, the expression of LNP formulated
sa-RNA peaked shortly (i.e., 24 h) after their administration. After
this peak, the expression dropped sharply. Formulation of sa-RNAs
into LNPs resulted, thus, in a faster and initial higher expression
than obtained after electroporation mediated delivery. This indicates
that LNPs cause a much more efﬁcient intracellular delivery of the
sa-RNA than electroporation (Figure 5A). LNPs escort all mRNA
into the cells without (excessive) degradation by extracellular RNases,
while injection of naked mRNA in combination with electroporation
presumably suffers from mRNA loss due to RNase degradation.
Furthermore, electroporation does not direct all mRNA into the cells,
resulting in a lower delivery efﬁciency. However, a strong innate
immune response is induced as a consequence of the massive intracel-
lular delivery of LNP-formulated sa-RNAs (Figure 8). This strong
IFN-b induction is most likely responsible for the sharp drop in
expression 24 h after administration of the sa-RNA-LNPs (Figure 5C).
However, at days 3–6, the drop in expression stopped, and a resur-
gence of the expression was noticed. This resurgence of the expression
was more pronounced at lower doses of the sa-RNA-LNPs. Lower
doses of the sa-RNA-LNPs are expected to induce a lower innate im-
mune response. Hence, it takes less time for the innate immune
response to drop below the “mRNA translation blockage threshold,”
and also, more RNAs are expected to survive this shorter and less
intense innate immune response. Due to this more pronounced and
faster resurgence of the expression, low doses of sa-RNA-LNPs
resulted, from day 5 onward until day 15, in a higher expression
than high doses of sa-RNA-LNPs. Nevertheless, the highest dose
(5 mg) of the sa-RNA-LNPs still resulted in a much higher expression
shortly after administration (i.e., day 1 until day 3). The remarkable
expression proﬁles in Figure 5C is, thus, due to a dose-depended
innate immune response and the capacity of the replicase complex
to generate many subgenomic mRNA copies from a few intact
sa-RNA strands. A similar resurgence, however, was not observed af-
ter electroporation of the sa-RNA. Therefore, the IFN-b response
Figure 4. The Extent and Duration of the Innate
Immune Responses after Intradermal
Electroporation of PBS, pDNA, sa-RNA, and
Unmodified and m1c-Modified mRNA
Five micrograms of each vector coding for EGFP was in-
jected on the flank of heterozygous IFN-b luciferase re-
porter mice. (A) In vivo bioluminescence was measured
starting 4 h after injection. Signal-to-background ratio was
calculated by dividing the bioluminescence signal in the
ROIs (total flux, photons per second [p/s]) by its back-
ground signal at day 1 for each mouse. Means + SD are
displayed (n = 6–8). (B) As a measure of the overall IFN-b
expression, the AUCs of the curves in (A) were calculated.
The horizontal bars represent the means. *p < 0.05; **p <
0.01; ***p < 0.001.
www.moleculartherapy.orginduced by electroporation of sa-RNA is, most likely, not strong
enough to cause a decrease in luciferase expression.
A very interesting observation was the presence of a short-lived
expression (up to 48 h after administration; data not shown) in the
draining subiliac lymph node after intradermal delivery of sa-RNA-
LNPs (Figures 6 and 7). Expression of luciferase in the lymph nodes
can be the result of the transport of the sa-RNA-LNPs toward the
draining lymph nodes or due to migration of transfected immune
cells at the injection site toward the draining lymph nodes. The lucif-
erase protein expressed at the site of injection can also be transported
to the lymph nodes. Further research is necessary to determine how
the lymph nodes get luciferase positive and which types of cells are
transfected. Nevertheless, this expression in the lymph nodes mostlikely indicates transfection of APCs. Therefore, formulation of
sa-RNAs into LNPs is expected to genuinely boost the efﬁcacy of
sa-RNA vaccines as was also shown by Geall et al.50,51
In conclusion, we demonstrated that in vivo intradermal electro-
poration of a VEEV-based sa-RNA outperformed the expression
obtained after electroporation of pDNA or non-replication mRNAs.
Furthermore, in vivo electroporation of our sa-RNA resulted in a
short-lived and moderate innate immune response that did not affect
the expression of the sa-RNA. When the VEEV-based sa-RNA was
encapsulated in LNPs, a completely different expression and innate
immune response proﬁle was obtained. The expression rapidly
peaked 24 h after intradermal injection of sa-RNA-LNPs and subse-
quently showed a sharp drop that can be attributed to a massiveFigure 5. Lipid Nanoparticle versus Electroporation-
Mediated Intradermal Delivery of sa-RNA
(A) Three mice per group were intradermally injected on
both flanks with 5 mg of either sa-RNA-LNPs, naked sa-
RNA, or naked sa-RNA followed by electroporation. In vivo
bioluminescence wasmeasured over 4 weeks, andmean ±
SEM of the total flux in the ROIs is displayed. The injection
site was chosen as the ROI and did not include the area of
the draining lymph nodes. The dotted line represents the
background signal, and the shaded area indicates a sig-
nificant difference between luciferase expression after use
of LNPs versus electroporation. (B) AUC (mean ± SEM) of
the expression kinetic curves shown in (A) was calculated
and displayed to compare total protein expression between
the different delivery systems. Individual values are plotted
with themean. (C) In vivo bioluminescence after intradermal
injection of 5, 1, or 0.1 mg sa-RNA encapsulated in LNPs.
(D) The calculated AUCs of the curves in (C). The shaded
area indicates that the luciferase expression after injection
of 5 mg sa-RNA-LNPs is significantly higher than 1 mg and
0.1 mg. Mean ± SEM are displayed. The arrows indicate the
time points at which the expression resurgences. *p < 0.05.
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Figure 6. Bioluminescence Images of Four Mice after Intradermal Injection of 5 mg sa-RNA Encapsulated in LNPs
(A and B) In vivo bioluminescence images of (A) the untreated contralateral (negative) flanks and (B) the treated ipsilateral (positive) flanks, respectively, 5 h after injection of
sa-RNA-LNPs. Next to the bright bioluminescent spot, which is the injection spot, a small bioluminescent spot is visible at the location of the draining subiliac lymph node (B).
Twenty-four hours after injection of the sa-RNA-LNPs, the subiliac lymph nodes were excised, and ex vivo bioluminescent images were taken. (C) and (D) show, respectively,
the draining subiliac lymph nodes of the untreated contralateral (negative) flanks and treated ipsilateral (positive) flanks that received sa-RNA-LNPs.
Molecular Therapy: Nucleic Acidsinduction of the innate immune system. Interestingly, intradermal
injection of sa-RNA-LNPs also resulted in a protein expression in
the lymph nodes, which supports the potential use of sa-RNA-
LNPs as vaccines. However, it needs to be examined whether
the induced innate immune response after administration of the
sa-RNA-LNPs is balanced enough to potentiate adaptive immune
responses. Indeed, it has been shown that a too-high innate im-




Female wild-type BALB/cJRj mice were purchased from Janvier Labs
(Le Genest-Saint-Isle, France) and housed in individual ventilated ca-
ges in a climate-controlled facility under a 14-h/10-h light/dark cycle.
Heterozygous IFN-b reporter mice with a BALB/c background were a
kind gift of Johan Grooten,54 and the breed was further maintained in
house. Shortly, the mice were genetically modiﬁed by replacing the
IFNB gene with the luciferase reporter gene, placing the reporter un-
der the control of an IFNB promoter. The IFN-b reporter mice used
in our study were heterozygotes, which implies that they can produce874 Molecular Therapy: Nucleic Acids Vol. 17 September 2019IFN-b and have a functional IFN-b pathway.Wemeasured the induc-
tion of IFN-b by in vivo bioluminescence imaging after systemic
administration of luciferin. All mice were aged between 7 and
10 weeks at the start of the experiments and kept in individually venti-
lated cages with ad libitum access to food and water. The in vivo
mouse experiments were conducted with the approval of the ethical
committee of the Faculty of Veterinary Medicine, Ghent University
(EC2016/17).
Plasmid Constructs
Bacteria containing the pGL4.13 plasmid (GenBank: AY738225)
were a kind gift of Katrien Remaut (Ghent University). This
plasmid from Promega (Madison, WI, USA) encodes the reporter
gene luciferase (luc2) from P. pyralis, controlled by the SV40 pro-
moter, and was used to examine expression kinetics. Similarly, a
pDNA (pEGFP-N1, GenBank: U55762.1) encoding EGFP and con-
taining 321 CpG motifs55 was used to study the IFN-b response
after intradermal electroporation of pDNA in reporter mice.
E. coli containing the pEGFP-N1 were also a kind gift of Katrien
Remaut. This plasmid contains the EGFP gene controlled by a
cytomegalovirus (CMV) promoter.
Figure 7. Comparison of the In Vivo and Ex Vivo Bioluminescence Signals
in the Draining Lymph Nodes after Intradermal Injection of 5 mg sa-RNA-
LNPs
The in vivo bioluminescence signals were measured 5 h after intradermal injection.
Twenty-four hours after injection of the sa-RNA-LNPs, mice were euthanized, and
the subiliac lymph nodes were excised and drippedwith luciferin immediately before
measurement. LN+, ipsilateral lymph node draining the injection spot. LN, the
contralateral lymph node. Horizontal bars represent the mean (n = 4). **p < 0.01;
***p < 0.001.
www.moleculartherapy.orgFurther, we used 4 different plasmids for the production of RNA by
IVT. pTK160 (11,519 bp) and pMC15 (10,586 bp) are derived from
VEEV strain TC-83 containing a substitution in the 50 UTR (r.3a >
g) and in nsP2 (p.Q739L). The sequence coding for the structural pro-
teins was replaced by the reporter gene luc2 or EGFP, respectively,
corresponding to the sequences used in pGL4.13 and pEGFP-N1.
Additionally, the vectors contained restriction sites for the I-SceI
endonuclease prior to a T7 polymerase promoter and downstream
of a short poly(A) sequence. pTK305 (4,112 bp)45 and pMC13
(3,179 bp) plasmids were used to produce (modiﬁed) mRNA contain-
ing, respectively, the luc2 or the EGFP reporter gene. These plasmids
contain, besides the reporter genes, VEEV-derived 50 and 30 UTRs
and were constructed using standard Gateway cloning procedures.
In short, the EGFP sequence was derived from the peGFP-N1 plasmid(a kind gift of Dr. Katrien Remaut) using attB-containing primers.
The EGFP cassette of the entry clone (pENTR221-EGFP) was in-
serted into destination vector pTK155 or pTK318 for the sa-RNA
or (un)modiﬁed mRNA, respectively, using LR clonase II (Thermo
Fisher Scientiﬁc, Waltham, MA, USA). These destination vectors
(kind gifts from Tasuku Kitada and Ron Weiss) contain an attR1-
ccdB-ChloramphenicolR-attR2 sequence that allowed site-speciﬁc
recombination with the attL1-eGFP-attL2 from pENTR221-EGFP
to generate pMC15 and pMC13, respectively. The pTK160 and
pTK305 plasmids, containing the Fluc2 sequence from pGL4 (Prom-
ega), were produced in a similar fashion and were also a kind gift of
Tasuku Kitada and Ron Weiss.
E. coli bacteria containing the plasmids were cultivated in lysogeny
broth (LB; Invitrogen, Waltham, MA, USA), and the plasmids
were subsequently isolated using the EndoFree Plasmid Maxi Kit
(QIAGEN) when pDNA was used for injection or the Plasmid Plus
Midi Kit (QIAGEN) when further processed to mRNA.mRNA Synthesis
Template DNA was generated by linearizing the aforementioned
plasmids using I-SceI endonuclease (New England Biolabs, Ipswich,
MA, USA) before IVT with the MEGAscript T7 Transcription Kit
(Life Technologies, Waltham, MA, USA). Post-transcriptional
modiﬁcations were applied using the ScriptCap m7G Capping Sys-
tem, 20-O-Methyltransferase Kit, and the A-Plus Poly(A) Polymerase
Tailing Kit (CELLSCRIPT, Madison, WI, USA). All mRNAs were pu-
riﬁed with the RNeasy Mini Kit (QIAGEN) after IVT and after each
modiﬁcation. For production of modiﬁed mRNA, the uridine nucle-
otide was completely replaced by N1-methylpseudouridine (tebu-bio,
Boechout, Belgium) during IVT. Correct translation of EGFP-encod-
ing IVT mRNAs and pDNA was veriﬁed after transfection of baby
hamster kidney (BHK) cells using Lipofectamine MessengerMAX
(Thermo Fisher Scientiﬁc) and subsequent evaluation using the
Nikon Eclipse Ti-S ﬂuorescent microscope (Nikon, Leuven, Belgium).Injection, Electroporation, and LNPs
Different doses of pDNA and mRNA (ranging from 0.01 to 10 mg)
were dissolved in 50 mL PBS, and 1 U RNasin Plus RNase InhibitorFigure 8. Kinetics of the Type I Interferon Immune
Response after Lipid-Nanoparticle-Mediated
Delivery of sa-RNA
(A) The extent and kinetics of the IFN-b induction in reporter
mice after LNP- and electroporation-mediated intradermal
delivery of 5 mg sa-RNA encoding EGFP was measured by
in vivo bioluminescence imaging. The in vivo biolumines-
cence was measured starting 4 h after injection and was
further monitored for 2 weeks. Signal-to-background ratios
were calculated by dividing the bioluminescence signals in
the ROIs (total flux, p/s), with its background signal at
day 1 for each mouse. Means ± SD are displayed (n = 8).
(B) As a measure of the overall IFN-b expression, the AUCs
of the curves in (A) were calculated. Individual values are
plotted with the mean. *p < 0.05; ****p < 0.0001.
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Molecular Therapy: Nucleic Acids(Promega) per microliter of solution was added to the mRNA before
storing the solution at80C. Mice were sedated using the inhalation
anesthetic isoﬂurane, at 5% for induction and 2% for maintenance,
and were shaved to decrease photon scattering and absorption by
the fur during the luciferase-mediated conversion of luciferin. Injec-
tions were performed intradermally on one or both ﬂanks of the mice
using a 29G insulin needle (VWR, Amsterdam, the Netherlands).
Electroporation, when used, was executed immediately after each in-
jection with a 2-needle array electrode containing 4 needles per row of
4 mm (AgilePulse, BTX Harvard Apparatus, Holliston, MA, USA) as
previously described.56 In brief, 2 short high-voltage pulses were given
(450 V, 0.05 ms), followed by 8 long low-voltage pulses (100 V, 10ms)
and an interval of 300 ms between each pulse. sa-RNAs coding for
EGFP or luciferase were also encapsulated in LNPs, as previously
described.57 Brieﬂy, an ethanolic lipid solution was rapidly mixed
with an aqueous solution containing sa-RNA (pH 4). The lipid solu-
tion consists of ionizable lipids, phosphatidylcholine, cholesterol, and
PEG in a 50/10/38.5/1.5 ratio, respectively. The RNA-loaded particles
were characterized and subsequently stored at80C at a concentra-
tion of 1 mg/mL. The mean hydrodynamic diameter of these sa-RNA-
LNPs was 72 ± 3 nm, with a polydispersity index of 0.032 ± 0.009, and
the zeta potential equaled6 ± 1 mV (Zetasizer Nano ZS90, Malvern
Panalytical, Worcestershire, UK). The encapsulation efﬁciency was
determined by RiboGreen RNA Assay Kit (as described previously)58
and equaled 95.8% ± 1.0%.Bioluminescence Imaging
Mice were intraperitoneally injected with 200 mL D-luciferin (15 mg/
mL, Gold Biotechnology, Olivette, MO, USA), and in vivo biolumi-
nescent imaging was performed 15 min later using an IVIS Lumina
II (PerkinElmer, Zaventem, Belgium). The total ﬂux in the region
of interest was determined using the Living Image Software v4.3.1.
In vivo bioluminescence imaging was repeated at different time points
to study the expression kinetics of pDNA and the different mRNA
vectors.Statistical Analysis
Statistical analysis and development of the graphs were performed
with the software GraphPad Prism 6 (GraphPad Software, San Diego,
CA, USA). Longitudinal experiments were analyzed with repeated-
measures two-way ANOVA, followed by Sidak’s or Tukey’s multiple
comparisons test. Fixed-time point analysis was performed using a
ratio paired t test, and outliers were determined using Grubbs’ test.
Differences are found to be signiﬁcant when the p value was <0.05
(*p < 0.05; **p < 0.01; ***p < 0.001; and ****p < 0.0001).AUTHOR CONTRIBUTIONS
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